Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past ...

Have you assessed how the international operations of Moderna (MRNA) performed in the quarter ended December 2024? For this biotechnology company, possessing an expansive global footprint, parsing the ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against firms ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...

Allspring Global Investments Holdings LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 12.2% in the fourth quarter, Holdings Channel reports. The firm owned 15,368 shares of ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...